Drug Approval | March 01, 2023
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
Experts’ conclave to pave holistic approach to cancer management
AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
The product is backed by required scientific proof and comparative bioequivalence studies
Results reinforce commitment to next-generation oral SERD development programme
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Subscribe To Our Newsletter & Stay Updated
